In 143 PD-L1+ (≥ 1% PD-L1 combined positive score) patients: ORR: 13.3%; DOR: 2.8 to 19.4+ months; 58% of responses lasted 6+ months; 26% of responses lasted 12+ months; PD-L1 combined positive score was the% of PD-L1+ tumor and immune cells relative to tumor cells, Dako PD-L1 IHC 22C3 pharmDx kit. This evidence concerns the gene CD274 and neoplasm.